Kyowa Kirin Group Expands in China, Introduces Innovative Medications for Hematology, Oncology, and Rare Diseases, Japan

Date:

Kyowa Kirin Group, the Japanese pharmaceutical company, is expanding its presence in China by introducing innovative medications for hematology, oncology, and rare diseases. The company plans to increase its investments in the Chinese market and offer a broader range of medications targeting various medical conditions. A senior executive from the company expressed optimism about the Chinese market and emphasized the commitment to delivering high-quality medicines and services to benefit more patients in China.

To enhance its production and logistics strength in China, Kyowa Kirin recently launched an expansion project at its manufacturing base in Shanghai. With an investment of approximately 100 million yuan ($13.67 million), the expansion project took 15 months to complete and covers a total construction area of 6,300 square meters. The newly expanded facility includes production areas, storage facilities, and office spaces, with a primary focus on expanding production and increasing storage capacity for newly introduced biopharmaceutical medicines.

According to Lisa Li, the general manager of Kyowa Kirin China, the expansion aims to boost the production of innovative biopharmaceuticals that have received approval overseas but are either recently approved in China or awaiting approval. With the expanded facility, the company’s production capacity in Shanghai will be doubled, while its storage areas are designed for the storage and distribution of semi-finished and finished products.

The new warehouse is equipped with a fully automated three-dimensional storage system, offering a total capacity of 2,520 storage locations, including 840 cold storage spaces. The implementation of an intelligent system enhances operational efficiency and space utilization, significantly elevating the level of intelligent management within the company. Additionally, the associated distributed photovoltaic project, which is now connected to the grid, is expected to reduce carbon emissions by 300 metric tons annually.

See also  SAP Announces Executive Board Changes to Drive Cloud Growth and Customer Innovation

In line with China’s Healthy China 2030 initiative, which aims to promote overall health, Kyowa Kirin plans to accelerate the introduction of innovative drugs. The company has already successfully launched more than 10 innovative drugs in China, spanning areas such as hematology, oncology, nephrology, and rare diseases.

China has been taking steps to improve its business environment for drug innovation. In early July, the Ministry of Commerce organized a round-table discussion, inviting foreign pharmaceutical companies operating in China to share their operational status, problems, and concerns.

Kyowa Kirin Group’s expansion in China and its commitment to introducing innovative medications for various medical conditions reflect the company’s dedication to providing high-quality healthcare solutions. Through its increased investments and expanded production and logistics capabilities, Kyowa Kirin aims to contribute to the advancement of healthcare in China while benefiting a larger number of patients.

Frequently Asked Questions (FAQs) Related to the Above News

What is Kyowa Kirin Group?

Kyowa Kirin Group is a Japanese pharmaceutical company that specializes in developing medications for hematology, oncology, and rare diseases.

What are the company's plans in China?

The company plans to expand its presence in China by increasing investments and introducing innovative medications targeting various medical conditions.

What recent expansion project did Kyowa Kirin launch in China?

Kyowa Kirin launched an expansion project at its manufacturing base in Shanghai, investing approximately 100 million yuan ($13.67 million) to enhance production and logistics capabilities.

What does the expanded facility in Shanghai include?

The expanded facility includes production areas, storage facilities, and office spaces, with a focus on expanding production and increasing storage capacity for newly introduced biopharmaceutical medicines.

What is the purpose of the expansion project?

The expansion aims to boost the production of innovative biopharmaceuticals recently approved or awaiting approval in China, aligning with China's Healthy China 2030 initiative.

What is the capacity of the new warehouse?

The new warehouse has a fully automated three-dimensional storage system with a total capacity of 2,520 storage locations, including 840 cold storage spaces.

How will the expansion contribute to intelligent management and carbon emissions reduction?

The implementation of an intelligent system enhances operational efficiency, and the associated distributed photovoltaic project is expected to reduce carbon emissions by 300 metric tons annually.

How many innovative drugs has Kyowa Kirin already launched in China?

Kyowa Kirin has successfully launched more than 10 innovative drugs in China, covering areas such as hematology, oncology, nephrology, and rare diseases.

What is the company's commitment to China?

Kyowa Kirin is committed to delivering high-quality healthcare solutions in China, contributing to the advancement of healthcare and benefiting a larger number of patients through increased investments and expanded capabilities.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

Global Edge Data Centers Market to Reach $46.4 Billion by 2030

Global edge data centers market set to hit $46.4 billion by 2030. Asia-Pacific leads growth with focus on IoT, cloud, and real-time analytics.

Baidu Inc Faces Profit Decline, Boosts Revenue with AI Advertising Sales

Baidu Inc faces profit decline but boosts revenue with AI advertising sales. Find out more about the company's challenges and successes here.

Alexander & Baldwin Holdings Tops FFO Estimates, What’s Next for the REIT?

Alexander & Baldwin Holdings surpasses FFO estimates, investors await future outlook in the REIT industry. Watch for potential growth.

Salesforce Stock Dips Despite New Dividend & Buyback

Despite introducing a new dividend & buyback, Salesforce's stock dipped after strong quarterly results. Investors cautious about future guidance.